Answers are grounded in this paper and cite their sources.
Cancer chemotherapy functions primarily by inducing apoptosis. Autophagy acts as a double-edged sword, serving to either promote tumorigenesis or mediate cell death. Recently, we reported that Theaflavins (TF) induced autophagy and cell death in Ehrlich ascites carcinoma cells at 4 h, well before the onset of apoptosis. Here, we report that TF induced ∼8–9% cell death in MCF7, HepG2, and HeLa cells at 8 h. Autophagy was evident from an increase in MDC+ autophagosomes, augmented LC3-II levels, and enhanced autophagic flux. Increased LC3 puncta in MCF7 cells, as well as early (AVi) and late (AVd) autophagosomes in HepG2 cells were also detected. TF-induced autophagy might be associated with cell death and increased oxygen consumption rate (OCR), elevated reactive oxygen species (ROS) production, and mitochondrial membrane potential (ΔΨM) depolarization prior to the commencement of apoptosis. Furthermore, TF-induced autophagy, suggestively, occurred via a Beclin-1-independent non-canonical pathway, as indicated by downregulated Beclin-1 expression and the failure of 3-methyladenine (3-MA, a canonical autophagy inhibitor) to suppress it. Together, these findings indicate that TF-induced cell death in MCF7 and HepG2 cells is initiated plausibly through a Beclin-1-independent non-canonical autophagy-associated pathway that precedes apoptosis by regulating ROS generation and ΔΨM.
No takes yet. Share an insight, caveat, or question.
Ghosh et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: